Trials / Terminated
TerminatedNCT00490776
Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)
A Phase II Study of Oral LBH589 in Adult Patients With Cutaneous T-Cell Lymphoma Who Are Intolerant to or Have Progressed on or After Prior HDAC Inhibitor
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluated the safety and efficacy of LBH589B in adult participants with refractory/resistant Cutaneous T-Cell Lymphoma and prior Histone Deacetylase (HDAC) inhibitor therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Panobinostat | Panobinostat, 20 mg, hard gelatin capsules, orally, thrice weekly. |
Timeline
- Start date
- 2007-07-05
- Primary completion
- 2009-09-01
- Completion
- 2009-09-22
- First posted
- 2007-06-25
- Last updated
- 2021-08-18
- Results posted
- 2021-06-18
Locations
18 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00490776. Inclusion in this directory is not an endorsement.